Skip to Content

For more information about Ascendis, please visit us at ascendispharma.us or follow Ascendis on Twitter and LinkedIn.

Visit LivingHypoPara.com to learn more about hypoPARAthyroidism and to gain access to our library of lifestyle tips and wellness resources.

Expanded Access Program (EAP)  EAP criteria

As of 15 August 2024, all but one US clinical trial site (whose study participants aren’t scheduled to complete clinical trial treatment until March 2025) are either enrolled in the EAP or have applications in process to become an EAP site. Any physicians interested in referring patients to an EAP site can contact Ascendis by phone at 1-844-442-7236 or by submitting a request form at https://ascendispharmamedinfo.us. Processing of in-process applications to become an EAP site will continue - but it’s important to note these applications are governed by the physician’s institutional contracting and IRB process, for which Ascendis has no oversight. We will continue to meet with each clinical trial and EAP site as needed to address any questions they may have.

Once a patient is referred to an EAP site, the EAP treating physician may require transfer of medical histories or other information for their records, but EAP patient enrollment requires only 3 forms:

    • Patient Access Form, required to establish the patient as part of the EAP
    • An eligibility questionnaire (7 questions that can be completed via email)
    • Patient consent form (reviewed with patient by physician or staff, then signed by patient)

Yorvipath approval press release

What is Yorvipath?

Yorvipath is a prodrug of parathyroid hormone (PTH 1-34) administered by injection once daily. Previously known as Transcon PTH in the USA it has shown very good results in Phase III trials with patients able to come off calcium and Calcitriol and improve kidney function and quality of life. PubMed article

Learn all you can about Yorvipath so you can have a discussion with your doctor about if it's right for you. Visit the Ascendis website for more information. Visit the Ascendis website for more information. Full Prescribing Information Ascendis Pharma Yorvipath page